India’s frugal crisis could prove a false economy

India’s scarring might run deeper than the latest economic results suggest. The country’s gross domestic product (GDP) contracted by 7.5 per cent in the quarter through September from a year earlier, compared to a record 23.9 per cent decline in the previous quarter. The result also was better than forecasts compiled by Reuters, but potentially masks the outsized after-effects the pandemic will have on a nation that was one of the world’s biggest drivers of growth before the pandemic.

Agriculture, which occupies about half the workforce, continued a positive run. Manufacturing swung narrowly back to growth, from a 39 per cent contraction in the prior three-month period. Investment dropped just 7 per cent compared to a stunning 47 per cent earlier dip. Private consumption also improved. However, corporate cost-cutting may be supporting profit in a way that flatters the data. Government consumption shrunk a sharp 22 per cent from the same quarter in 2019.

Also read: As RBI continues to buy dollars, rupee falls even as most Asian currencies rise

Policymakers nearly everywhere have forcefully responded to Covid-19, splashing out an unprecedented $11.7 trillion, or close to 12 per cent of global GDP, as per International Monetary Fund figures. By contrast, New Delhi has mapped a frugal course. By one measure focused on government budget balance, India’s adjusted fiscal response has been less than half the emerging-market average of 4.1 percentage points and is well short of the average 8 percentage points for advanced economies, Citi notes. The conservatism has helped India hang onto an investment-grade credit rating.

It could prove a false economy, though. GDP per capita in 2025 may end up 12 per cent below pre-crisis estimates, ranking India’s pandemic outcome amongst the worst in the world, reckons Priyanka Kishore from Oxford Economics. More spending now and a gradual phasing out of support might leave central government debt at half of GDP, up only around three percentage points from 2019.

In the absence of more official generosity in the $2.6-trillion economy, India’s best hope is to capitalise on a vaccine advantage. The country is among the largest producers, and manufacturers such as the Serum Institute are already stockpiling AstraZeneca’s formulation. Inoculations need approvals and distributing them to enough of the 1.3 billion population will be an enormous challenge. It is nevertheless a development that could really move India’s economic needle.

On Twitter https://twitter.com/ugalani

(The author is a Reuters Breakingviews columnist. The opinions expressed are her own.)

COMMENT NOW